| Previous Close | 4.85 |
| Open | 4.90 |
| Bid | 5.25 x 2500 |
| Ask | 5.30 x 6600 |
| Day's Range | 4.87 - 5.40 |
| 52 Week Range | 2.40 - 6.45 |
| Volume | 1,019,557 |
| Avg. Volume | 1,290,801 |
| Market Cap | 144.71M |
| Beta | 0.76 |
| PE Ratio (TTM) | -5.12 |
| EPS (TTM) | -1.03 |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- Benzinga•6 hours ago
Mylan's Stock Is No Longer A Buy According To Analysts At Argus
Analysts at Argus no longer hold a bullish view on Mylan N.V. (NASDAQ: MYL ) after the company cut its full-year guidance and cautioned that its earnings per share will decline in 2017. The firm's Jasper ...
- ACCESSWIRE•8 days ago
Today's Research Reports on Stocks to Watch: Adamis Pharmaceuticals and Mylan
NEW YORK, NY / ACCESSWIRE / August 14, 2017 / While shares of Mylan continued to suffer last Friday, competitor Adamis Pharmaceuticals saw gains. Adamis has an Epinephrine injection that is a generic version ...
- Zacks•2 months ago
Adamis Gets FDA Nod for Generic Version of Mylan's EpiPen
Shares of Adamis Pharmaceuticals Corporation (ADMP) soared more than 50% after the FDA approved the company's Epinephrine injection, USP, (0.3 mg Pre-filled single dose syringe) which is the generic version of Mylan N.V.'s (MYL) EpiPen.
